RATIONALE: Heart failure (HF) is often the end phase of maladaptive cardiac hypertrophy. A contributing factor is activation of a hypertrophic gene expression program controlled by decreased class II histone deacetylase (HDAC) transcriptional repression via HDAC phosphorylation. Cardiac-specific overexpression of G proteinen-coupled receptor kinase-5 (GRK5) has previously been shown to possess nuclear activity as a HDAC5 kinase, promoting an intolerance to in vivo ventricular pressure overload; however, its endogenous requirement in adaptive and maladaptive hypertrophy remains unknown. OBJECTIVE: We used mouse models with global or cardiomyocyte-specific GRK5 gene deletion to determine the absolute requirement of endogenous GRK5 for cardiac hypertrophy and HF development after chronic hypertrophic stimuli. METHODS AND RESULTS: Mice with global deletion of GRK5 were subjected to transverse aortic constriction. At 12 weeks, these mice showed attenuated hypertrophy, remodeling, and hypertrophic gene transcription along with preserved cardiac function. Global GRK5 deletion also diminished hypertrophy and related gene expression due to chronic phenylephrine infusion. We then generated mice with conditional, cardiac-specific deletion of GRK5 that also demonstrated similar protection from pathological cardiac hypertrophy and HF after transverse aortic constriction. CONCLUSIONS: These results define myocyte GRK5 as a critical regulator of pathological cardiac growth after ventricular pressure overload, supporting its role as an endogenous (patho)-physiological HDAC kinase. Further, these results define GRK5 as a potential therapeutic target to limit HF development after hypertrophic stress.
RATIONALE: Heart failure (HF) is often the end phase of maladaptive cardiac hypertrophy. A contributing factor is activation of a hypertrophic gene expression program controlled by decreased class II histone deacetylase (HDAC) transcriptional repression via HDAC phosphorylation. Cardiac-specific overexpression of G proteinen-coupled receptor kinase-5 (GRK5) has previously been shown to possess nuclear activity as a HDAC5 kinase, promoting an intolerance to in vivo ventricular pressure overload; however, its endogenous requirement in adaptive and maladaptive hypertrophy remains unknown. OBJECTIVE: We used mouse models with global or cardiomyocyte-specific GRK5 gene deletion to determine the absolute requirement of endogenous GRK5 for cardiac hypertrophy and HF development after chronic hypertrophic stimuli. METHODS AND RESULTS:Mice with global deletion of GRK5 were subjected to transverse aortic constriction. At 12 weeks, these mice showed attenuated hypertrophy, remodeling, and hypertrophic gene transcription along with preserved cardiac function. Global GRK5 deletion also diminished hypertrophy and related gene expression due to chronic phenylephrine infusion. We then generated mice with conditional, cardiac-specific deletion of GRK5 that also demonstrated similar protection from pathological cardiac hypertrophy and HF after transverse aortic constriction. CONCLUSIONS: These results define myocyte GRK5 as a critical regulator of pathological cardiac growth after ventricular pressure overload, supporting its role as an endogenous (patho)-physiological HDAC kinase. Further, these results define GRK5 as a potential therapeutic target to limit HF development after hypertrophic stress.
Authors: Takahisa Noma; Anthony Lemaire; Sathyamangla V Naga Prasad; Liza Barki-Harrington; Douglas G Tilley; Juhsien Chen; Philippe Le Corvoisier; Jonathan D Violin; Huijun Wei; Robert J Lefkowitz; Howard A Rockman Journal: J Clin Invest Date: 2007-09 Impact factor: 14.808
Authors: Ralph J van Oort; Eva van Rooij; Meriem Bourajjaj; Joost Schimmel; Maurits A Jansen; Roel van der Nagel; Pieter A Doevendans; Michael D Schneider; Cees J A van Echteld; Leon J De Windt Journal: Circulation Date: 2006-07-17 Impact factor: 29.690
Authors: Stephen B Liggett; Sharon Cresci; Reagan J Kelly; Faisal M Syed; Scot J Matkovich; Harvey S Hahn; Abhinav Diwan; Jeffrey S Martini; Li Sparks; Rohan R Parekh; John A Spertus; Walter J Koch; Sharon L R Kardia; Gerald W Dorn Journal: Nat Med Date: 2008-04-20 Impact factor: 53.440
Authors: Xu Wu; Tong Zhang; Julie Bossuyt; Xiaodong Li; Timothy A McKinsey; John R Dedman; Eric N Olson; Ju Chen; Joan Heller Brown; Donald M Bers Journal: J Clin Invest Date: 2006-03 Impact factor: 14.808
Authors: Rick B Vega; Brooke C Harrison; Eric Meadows; Charles R Roberts; Philip J Papst; Eric N Olson; Timothy A McKinsey Journal: Mol Cell Biol Date: 2004-10 Impact factor: 4.272
Authors: Shurong Chang; Timothy A McKinsey; Chun Li Zhang; James A Richardson; Joseph A Hill; Eric N Olson Journal: Mol Cell Biol Date: 2004-10 Impact factor: 4.272
Authors: Helen V Waldschmidt; Renee Bouley; Paul D Kirchhoff; Pil Lee; John J G Tesmer; Scott D Larsen Journal: Bioorg Med Chem Lett Date: 2018-03-30 Impact factor: 2.823
Authors: Jonathan E Hullmann; Laurel A Grisanti; Catherine A Makarewich; Erhe Gao; Jessica I Gold; J Kurt Chuprun; Douglas G Tilley; Steven R Houser; Walter J Koch Journal: Circ Res Date: 2014-10-20 Impact factor: 17.367
Authors: Kristoff T Homan; Helen V Waldschmidt; Alisa Glukhova; Alessandro Cannavo; Jianliang Song; Joseph Y Cheung; Walter J Koch; Scott D Larsen; John J G Tesmer Journal: J Biol Chem Date: 2015-06-01 Impact factor: 5.157
Authors: Christopher J Traynham; Alessandro Cannavo; Yan Zhou; Alexandre G Vouga; Benjamin P Woodall; Jonathan Hullmann; Jessica Ibetti; Jessica I Gold; J Kurt Chuprun; Erhe Gao; Walter J Koch Journal: Circ Res Date: 2015-10-29 Impact factor: 17.367
Authors: Ashbeel Roy; William C Fields; Cibele Rocha-Resende; Rodrigo R Resende; Silvia Guatimosim; Vania F Prado; Robert Gros; Marco A M Prado Journal: FASEB J Date: 2013-09-09 Impact factor: 5.191